Boothbay Fund Management’s AbbVie ABBV Stock Holding History

Boothbay Fund Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-26,700	Closed	-$4.14M	–	1532
2023 Q4	$4.14M	Hold	26,700	–	–	0.11%	259
2023 Q3	$3.98M	Buy	+26,700	New	+$3.92M	0.09%	284
2023 Q1	–	Sell	-35,200	Closed	-$5.69M	–	2087
2022 Q4	$5.69M	Sell	35,200 -110,000	-76%	-$16.9M	0.13%	188
2022 Q3	$19.5M	Buy	145,200 +142,200	+4,740%	+$20.4M	0.49%	13
2022 Q2	$459K	Sell	3,000 -5,400	-64%	-$825K	0.01%	1219
2022 Q1	$1.36M	Buy	+8,400	New	+$1.22M	0.03%	755
2020 Q2	–	Sell	-113	Closed	-$861K	–	938
2020 Q1	$861K	Buy	+113	New	+$9.63K	0.07%	334

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boothbay Fund Management's ABBV Position: Q1 2026 in Review

Boothbay Fund Management increased its AbbVie (ABBV) stake by 34% in Q1 2026, buying an estimated $68.3K and bringing the position to 1,203 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #1665.

Boothbay Fund Management first reported a position in ABBV in Q3 2016 and has held it in 17 quarters since. The position peaked at $3.45M in Q3 2020. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Boothbay Fund Management held 1,203 shares of AbbVie worth $262K as of Q1 2026.
Boothbay Fund Management bought 308 AbbVie shares in Q1 2026, an estimated $68.3K.
AbbVie made up ﹤0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1665 holding.
Boothbay Fund Management first reported a position in AbbVie in Q3 2016 and has held it in 17 quarters since.
Boothbay Fund Management's AbbVie position peaked at $3.45M in Q3 2020.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.